Discover
CRBU
Caribou Biosciences, Inc.
1.76
3 x 1.70
2 x 2.21
bid
ask
+
0.00
0.00%
3 @ 04:08 AM
1.74 -0.02 (1.29%)
| Ytd | 10.69% | |
| 1y | 40.80% |
1.73
day range
1.78
1.24
52 week range
3.54
| Open | 1.76 | Prev Close | 1.76 | Low | 1.73 | High | 1.78 | Mkt Cap | 174.56M |
| Vol | 1.69M | Avg Vol | 1.90M | EPS | -1.42 | P/E | N/A | Forward P/E | -0.90 |
| Beta | 2.26 | Short Ratio | 4.55 | Inst. Own | 62.49% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 1.96 | 200-d Avg | 1.93 | 1yr Est | 12.50 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-06 | 2024-09 | -0.44 | -0.38 | 0.06 | 13.64% |
| 2024-08-06 | 2024-06 | -0.45 | N/A | N/A | N/A |
| 2024-08-06 | 2024-06 | -0.45 | -0.42 | 0.03 | 6.67% |
| 2024-05-07 | 2024-03 | -0.39 | N/A | N/A | N/A |
| 2024-05-07 | 2024-03 | -0.39 | -0.46 | -0.07 | -17.95% |
| 2024-03-11 | 2023-12 | -0.22 | -0.39 | -0.17 | -77.27% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-26 | Citigroup | Upgrade | Buy | Buy |
| 2024-11-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-09-03 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-07 | RBC Capital | Upgrade | Outperform | Outperform |
| 2024-07-17 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-11-19 | FISCHESSER RYAN M | Officer | 118.85K | Stock Award(Grant) |
| 2024-02-19 | HAURWITZ RACHEL E. PH.D. | Chief Executive Officer | 3.51M | Stock Award(Grant) |
| 2024-02-19 | KANNER STEVEN B. | Officer | 387.04K | Stock Award(Grant) |
| 2024-02-19 | KHAN RUHI AHMAD | Officer | 33.00K | Stock Award(Grant) |
| 2024-02-19 | MCCLUNG BARBARA G | Officer | 409.57K | Stock Award(Grant) |
| 2024-02-19 | O'BYRNE JASON | Chief Financial Officer | 59.22K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Blackrock Inc. | 7.23M | 12.95M | 7.99% |
| 2024-09-29 | Vanguard Group Inc | 4.62M | 8.27M | 5.10% |
| 2024-09-29 | Bank of America Corporation | 4.57M | 8.18M | 5.05% |
| 2024-09-29 | Pfm Health Sciences, Lp | 4.31M | 7.71M | 4.76% |
| 2024-09-29 | Kynam Capital Management, LP | 2.36M | 4.22M | 2.60% |
| 2024-09-29 | Elmwood Wealth Management, Inc. | 2.18M | 3.89M | 2.40% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 2.77M | 4.96M | 3.06% |
| 2024-10-30 | iShares Russell 2000 ETF | 2.18M | 3.90M | 2.41% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 1.23M | 2.20M | 1.36% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 846.69K | 1.52M | 0.94% |
| 2024-10-30 | iShares Russell 2000 Value ETF | 807.14K | 1.44M | 0.89% |
| 2024-10-30 | iShares Biotechnology ETF | 572.64K | 1.03M | 0.63% |